Parameters from HF rodents at 20–22 weeks postmyocardial infarction±SERCA2a gene therapy and AMCs
| AMC | HF | HF+SERCA | |
|---|---|---|---|
| LVEDP (mm Hg) | 8.25 (±1.47) | 18.31 (±8.19)* | 10.08 (±4.18) |
| HW:BW (g/kg) | 3.42 (±0.39) | 4.16 (±0.71)* | 4.16 (±0.48)* |
| LW:BW (g/kg) | 4.24 (±0.69) | 5.33 (±0.94)* | 4.76 (±0.52) |
| BW (g) | 431 (±53.23) | 441 (±73.15) | 471 (±29.01) |
| Wet:dry weight | 5.44 (±0.34) | 5.38 (±0.20) | 5.93 (±0.74) |
| Dry LW :B W (×10−4) | 1.87 (±0.20) | 3.60 (±1.43)* | 1.90 (±0.42)** |
Mean (±SD), n=5 in each group: *p<0.05 compared with AMC, **p<0.05 compared with myocardial infarction; Kruskal–Wallis with Dunn's post-test.
AMCs, age matched controls; BW, body weight; HF, heart failure; HW, heart weight; LVEDP, left ventricular end diastolic pressure; LW, lung weight.